Actinium Pharmaceuticals, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for ATNM, updated each market day.
ATNM AI Sentiment
AI sees no strong directional signal for Actinium Pharmaceuticals, Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Actinium Pharmaceuticals, Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Sector
Exchange
Market Cap
$35,767,493
Cap Tier
Employees
25
Headquarters
NEW YORK, NY
Listed Since
July 19, 2007
Website
ATNM Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ATNM Volatility
Actinium Pharmaceuticals, Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
